Shares of Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) surged about 2% on Friday as it loss of 17 cents a share in the Q4 of 2012 was a penny underneath the year-before loss and in-line with the Zacks Consensus anticipates.
The firm’s Q4 2012 revenues were $0.3M increased from ($0.7) million in the year-before period, but lower than the Zacks Consensus anticipates of $1M. Revenues in the year-earlier quarter suffered from a charge against revenues value $3.4M.
The firm reported that full-year 2012 adjusted net loss came in at 21 cents a share, lower than the year-before loss of 57 cents and the Zacks Consensus anticipates of a loss of 25 cents a share.
Shares of Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) opened at $4.18 with 133.88 million outstanding shares and touch its highest price of $4.33 of the day and then finished at $4.29 by scoring +1.90%, as in the whole session stocks gain volume of 694,142 shares which is lower than its average volume.
As the owner ship concerns stock institutional ownership remained 72.85% while insider ownership included 0.07%. The share capital of IDIX has 133.88 million outstanding shares amid them 100.24 million shares have been floated in market.
For investors focus on the performance of the stocks so the IDIX showed weekly behind performance of -5.51% which was maintained for the month at -7.14%. Correspondingly the negative performance for the quarter was remained -19.06% and if took notice on yearly performance that was -65.38% whereas the year to date performance halted at -11.55%.
As the moving toward the returns measures returns on Investment ratio is significant measure which investor should have in consideration, the IDIX return on investment was recorded as -16.76% as compare to its rivals has Gilead Sciences, Inc. (NASDAQ:GILD)’s ROI 16.27%, Cerus Corporation (NASDAQ:CERS)’s ROI -101.54%, Medivation, Inc. (NASDAQ:MDVN)’s ROI -9.98%, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’s ROI -42.64%.
Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Entire Disclaimer Here